Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin + cytarabine liposome
- Development stage
- Approved
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Vyxeos is a liposomal formulation containing a fixed 1:5 molar ratio of the antineoplastic agents daunorubicin and cytarabine. Developed by Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals) using the proprietary CombiPlex technology platform, it is designed to deliver a synergistic ratio of these two chemotherapies directly to the bone marrow and maintain that ratio intracellularly. Daunorubicin is an anthracycline that inhibits topoisomerase II and intercalates into DNA, while cytarabine is a pyrimidine analog that inhibits DNA polymerase, collectively inducing DNA damage and cell death. Vyxeos is specifically indicated for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC), which are high-risk subtypes associated with poor prognosis.
- Brand names
- Vyxeos
- Other names
- daunorubicin and cytarabine liposome for injection
02
Targets
DNA polymerase familyDNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on daunorubicin + cytarabine liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin + cytarabine liposome.